A Systematic Review and Meta-Analysis of the Efficacy and Safety of Rasagiline or Pramipexole in the Treatment of Early Parkinson’s Disease
Table 4
Change in UPDRS scores seen following pramipexole administration.
Change in UPDRS
Study, year
Time of assessment (from the start of the study)
Treatment
Part II
Part III
Total
Comments
Barone et al. 2010
5 wk.
PBO
NR
−1.0 ± 1.0
NR
UPDRS score had different number of patients PBO (n = 148), PPX (n = 139)
PPX
NR
−4.1±1.0
NR
12 wk.
PBO
−1.2 ± 0.3
−2.2 ± 0.5
NR
PPX
−2.4±0.3
−4.4±0.3
NR
Hauser et al. 2010
18 wk.
PBO
0.0 ± 0.5
−2.7 ± 1.0
NR
UPDRS scores had different number of patients PBO (n = 50), ER (n = 102), IR (n = 101). Levodopa data censored in the scores
PPX ER
−1.5±0.4
−5.9±0.9
NR
PPX IR
−1.8±0.4
−5.9±0.8
NR
Parkinson Study Group 2000a
23.5 mo.
PPX
1.1 ± 4.5
3.4 ± 8.6
4.5 ± 12.7
Values are reported from the whole study population (n = 301). Negative values indicated worsening and positive values indicated improvement
LD
2.2±3.2
7.3±8.6
9.2±10.8
Parkinson Study Group 2004
48 mo.
PPX
−1.7 ± 5.4
−1.3 ± 13.3
−3.2 ± 17.3
LD
−0.5±4.7
3.4±12.3
2.0±15.4
Kieburtz et al. 1997
10 wk.
PBO
NR
NR
−0.9 ± 9.1
The score in the parenthesis: secondary analysis of changes from baseline to 10 weeks in total UPDRS score. Difference between treatment group mean and placebo group mean. for all doses
PPX 1.5
NR
NR
−6.3 ± 9.0 (-5.24 (−8.95 to −1.54))
PPX 3.0
NR
NR
−5.9 ± 6.4 (-5.08 (−8.86 to −1.29))
PPX 4.5
NR
NR
−6.5 ± 8.2 (-5.86 (−9.59 to −2.13))
PPX 6.0
NR
NR
−7.0 ± 8.1 (-5.24 (−8.96 to −1.53))
Poewe et al. 2011
33 wk.
PBO
−0.2 (−0.9 to 0.4)
−1.1 (−2.5 to 0.3)
NR
N = 103 (PBO), N = 213 (ER), N = 207 (IR)
PPX ER
−2.1 (−2.5 to −1.6)
−6.1 (−7.1 to −5.1)
NR
PPX IR
−2.4 (−2.8 to −1.9)
−6.4 (−7.4 to −5.4)
NR
Schapira et al. 2013
6 to 9 mo.b
PBO
1.5 ± 0.2
2.7 ± 0.5
4.3 ± 0.6
N = 200 (PBO), N = 210 or 211 depending on time points (PPX)
Values are reported as mean ± standard deviation. ER = extended release, IR = immediate release, LD = levodopa, mo = months, NR = not reported, PBO = placebo PPX = pramipexole, UPDRS = the unified Parkinson’s disease rating scale, RR = ropinirole, and wk = weeks. aParkinson Study Group [34] reported the first 2 yr. of the study and Parkinson Study Group [35] reported results at the end of the 4-year study. bPatients were assigned to the pramipexole group at 9 months or as early as 6 months, if the patients expressed inability to tolerate PD symptoms. Statistically significant results are highlighted using bold text.